KPT-330 has antitumour activity against non-small cell lung cancer
Authors:
Open Access
- 19 June 2014
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 111 (2) , 281-291
Abstract
We investigated the biologic and pharmacologic activities of a chromosome region maintenance 1 (CRM1) inhibitor against human non-small cell lung cancer (NSCLC) cells both in vitro and in vivo. The in vitro and in vivo effects of a novel CRM1 inhibitor (KPT-330) for a large number of anticancer parameters were evaluated using a large panel of 11 NSCLC cell lines containing different key driver mutations. Mice bearing human NSCLC xenografts were treated with KPT-330, and tumour growth was assessed. KPT-330 inhibited proliferation and induced cell cycle arrest and apoptosis-related proteins in 11 NSCLC cells lines. Moreover, the combination of KPT-330 with cisplatin synergistically enhanced the cell kill of the NSCLC cells in vitro. Human NSCLC tumours growing in immunodeficient mice were markedly inhibited by KPT-330. Also, KPT-330 was effective even against NSCLC cells with a transforming mutation of either exon 20 of EGFR, TP53, phosphatase and tensin homologue, RAS or PIK3CA, suggesting the drug might be effective against a variety of lung cancers irrespective of their driver mutation. Our results support clinical testing of KPT-330 as a novel therapeutic strategy for NSCLC.Keywords
This publication has 53 references indexed in Scilit:
- Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomasHaematologica, 2013
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsLeukemia, 2012
- Chemotherapeutic Sensitization of Leptomycin B Resistant Lung Cancer Cells by Pretreatment with DoxorubicinPLOS ONE, 2012
- P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanismOncogene, 2011
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerCritical Reviews in Oncology/Hematology, 2010
- Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 InhibitionCancer Research, 2009
- Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivoCancer Research, 2009
- Therapeutic prospects for p73 and p63: Rising from the shadow of p53Drug Resistance Updates, 2008
- The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancersJournal of Clinical Investigation, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007